OTTAWA, Oct. 16 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap"
or "the Company") is pleased to report that a recent study titled "Kinases:
Advanced Strategies and Multiple Targets for Drug Discovery", predicts that
the global kinase-targeted drug market is set to grow at a compound annual
growth rate of approximately 36% over the next five years and is expected to
reach US$58.6 billion in sales of kinase-targeted pharmaceuticals by the end
of 2010. Cancer (mainly solid tumours) is expected to remain the dominant
application for targeted kinase therapies throughout the forecast period,
according to the study.
